Amended Current Report Filing (8-k/a)
August 17 2022 - 5:01PM
Edgar (US Regulatory)
0000109657
true
0000109657
2022-06-08
2022-06-08
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K/A
(Amendment
No. 1)
CURRENT
REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date
of Report:
(Date
of earliest event reported)
June
8, 2022
GT
Biopharma, Inc.
(Exact
name of registrant as specified in its charter)
Delaware
(State
or other Jurisdiction of Incorporation)
1-40023 |
|
94-1620407 |
(Commission
File Number) |
|
(IRS Employer
Identification No.) |
8000
Marina Blvd., Suite 100
Brisbane,
CA 94005
(Address
of Principal Executive Offices and zip code)
(800)
304-9888
(Registrant’s
telephone number, including area code)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of registrant under any
of the following provisions:
☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
☐ |
Soliciting
material pursuant to Rule 14a-12(b) under the Exchange Act (17 CFR 240.14a-12(b)) |
|
|
☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each Class |
|
Trading
Symbol(s) |
|
Name
of each Exchange on which registered |
Common
stock, $0.001 par value |
|
GTBP |
|
The
Nasdaq Stock Market LLC |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR 230.405)
or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR 240.12b-2).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Explanatory
Note
This
Amendment No. 1 to the Current Report on Form 8-K (this “Amendment”) is being filed by the Registrant for the purpose of
amending Item 5.07 Submission of Matters to a Vote of Security Holders of that certain Current Report on Form 8-K originally filed
by the Registrant with the Commission on June 14, 2022 (the “Original Form 8-K”), to provide additional disclosure regarding
the tabulation of votes at the annual meeting of the Registrant’s stockholders held on June 8, 2022 (the “Annual Meeting”),
on the proposal to amend the Registrant’s restated certificate of incorporation to reduce the number of authorized shares of the
Registrant’s common stock from 750,000,000 to 250,000,000 (“Proposal 4”).
Item
5.07. Submission of Matters to a Vote of Security Holders.
The
Registrant disclosed in the Original Form 8-K that the following summarized the vote results for Proposal 4:
4.
Proposal to amend the Registrant’s restated certificate of incorporation to decrease the authorized number of shares of the Registrant’s
common stock from 750,000,000 to 250,000,000.
For | |
Against | |
Abstain |
19,568,632 | |
215,253 | |
141,506 |
The
information reported by the Registrant in the Original Form 8-K was taken from the Final Report and Certification of the Inspector of
Election for the Annual Meeting reporting the tabulation of proxies and votes by the Inspector of Election for Proposal 4 as follows:
Proxies
were solicited on behalf of the Board of Directors of the Company and a vote was taken for the approval, of an amendment to the restated
certificate of incorporation to decrease the authorized number of shares of the common stock from 750,000,000 to 250,000,000. The proxies
and votes were delivered to and tabulated by me as Inspector of Election, and the results of the tabulation were as follows:
Votes For | |
Votes Against | |
Votes Abstained |
19,568,632 | |
215,253 | |
141,506 |
While
the definitive proxy statement for the Annual Meeting, filed with the Commission on April 29, 2022, indicated that Proposal 4 was a non-routine
matter for which broker discretionary voting was not allowed, Proposal 4 was, in fact, a routine matter for which broker discretionary
voting was allowed under applicable regulations. As a result, the Final Report and Certification of the Inspector of Election for the
Annual Meeting included discretionary votes by brokers or other nominees holding shares for Beneficial Owners in the tabulation of proxies
and votes on Proposal 4, resulting in the foregoing tabulation.
In
light of the determination that Proposal 4 was, in fact, a routine matter for which broker discretionary voting was permitted, and the
subsequent filing of a certificate of amendment to the Registrant’s restated certificate of incorporation to reduce the number
of authorized shares of the Registrant’s common stock from 750,000,000 to 250,000,000, the Registrant intends to hold a special
meeting of its stockholders to ratify the inclusion of discretionary votes by brokers or other nominees holding shares for beneficial
owners in the tabulation of votes on Proposal 4.
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
|
GT
BIOPHARMA, INC. |
|
|
|
|
Date: |
August
17, 2022 |
By: |
/s/
Manu Ohri |
|
|
|
Manu
Ohri |
|
|
|
Chief
Financial Officer and Secretary |
GT Biopharma (NASDAQ:GTBP)
Historical Stock Chart
From Oct 2024 to Nov 2024
GT Biopharma (NASDAQ:GTBP)
Historical Stock Chart
From Nov 2023 to Nov 2024